What a lot number proves — and what it does not

Reference page · published 2026-08-29

A lot number on a vial is a pointer. It points at a set of records — what was made, when, from what, tested how, by whom — that are supposed to exist somewhere else. The number itself proves nothing. Its whole value is whether the records it points to exist, and whether the person who printed it will produce them when asked.

“Lot/batch traceability” sits on most vendor-selection checklists in this category. It is usually left undefined. This page collects the primary sources that define it: the federal regulation the vocabulary comes from, the international definition of “traceability” that metrologists actually use, and the published analyses of what was in peptide vials when someone opened them and looked. None of it is an accusation against any vendor. It is the record, with the sources linked.

What a lot is — the definition the word comes from

The clearest written definition of a lot in this field is in the U.S. Code of Federal Regulations, in the part that governs drug manufacturing. Part 210 defines the terms:

“Batch means a specific quantity of a drug or other material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture.” — 21 CFR 210.3(b)(2)

“Lot means a batch, or a specific identified portion of a batch, having uniform character and quality within specified limits.” — 21 CFR 210.3(b)(10)

And then the part that matters for a buyer — what the number printed on the label is supposed to do:

“Lot number, control number, or batch number means any distinctive combination of letters, numbers, or symbols, or any combination of them, from which the complete history of the manufacture, processing, packing, holding, and distribution of a batch or lot of drug product or other material can be determined.” — 21 CFR 210.3(b)(11)

Read that definition slowly. A lot number is not defined by its format. It is defined by what can be determined from it: the complete history of the material. A string of characters from which nothing can be determined meets the format and fails the definition (source: eCFR, 21 CFR 210.3).

What sits behind the number when the system works

Part 211 of the same regulation spells out the records a lot number is meant to lead to. Four sections describe the chain.

The label must connect to the history. Packaging and labeling procedures must provide for identification of the drug product with a lot or control number that permits determination of the history of the manufacture and control of the batch (21 CFR 211.130(c)).

The batch record must say what went in. A batch production and control record is prepared for each batch and must include, among thirteen listed items, specific identification of each batch of component or in-process material used, the weights and measures of components used in the course of processing, the in-process and laboratory control results, and a statement of the actual yield (21 CFR 211.188). So a real lot record traces backward: this lot was made from these inputs, which were themselves lots.

The laboratory record must tie the test to the lot. Laboratory records must include a description of the sample received for testing with identification of source (that is, location from where sample was obtained), quantity, lot number or other distinctive code, date sample was taken, and date sample was received for testing, and a complete record of all data secured in the course of each test, including all graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, drug product container, closure, in-process material, or drug product, and lot tested. Two sign-offs are required — the initials or signature of the person who ran the test, and of a second person who reviewed the record (21 CFR 211.194(a)). Release itself requires appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).

A piece of the lot must be kept. This is the part almost nobody outside manufacturing knows about. An appropriately identified reserve sample that is representative of each lot or batch of drug product shall be retained and stored under conditions consistent with product labeling. It must be at least twice the quantity necessary to perform all the required tests, kept in the same kind of container the product ships in, and retained for 1 year after the expiration date of the drug product (21 CFR 211.170(b)). The purpose is plain: if a question about a lot comes up after it has shipped, there is still material from that lot to test.

Put together, that is what “traceability” means in the regulation the word comes from. A number on the label leads to a batch record, which leads to component lots and test results, which are tied to a named sample on a dated sheet with the instrument output attached, signed twice — and a physical sample of the lot is still on a shelf. Whether any of that exists behind the number on a given vial is not something the number can tell you.

Two things this page does not claim. Part 211 is written for manufacturers of finished drug products; nothing here assumes that any research-reagent supplier keeps this record set, and a listing that carries a lot number makes no such statement. The regulation is quoted because it is the most explicit written description anywhere of what a lot number is for.

“Traceability” has a second meaning — and a certificate usually has neither

The same word is used by measurement scientists for something different. The international vocabulary of metrology (JCGM 200:2012, known as the VIM) defines metrological traceability as the

“property of a measurement result whereby the result can be related to a reference through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty.” — JCGM 200:2012, definition 2.41

The notes attached to the definition matter as much as the sentence. Metrological traceability requires an established calibration hierarchy, and the specification of the reference must include the time at which this reference was used in establishing the calibration hierarchy (BIPM, JCGM 200:2012). Lot traceability asks “where did this material come from?” Metrological traceability asks “where did this number come from, and how uncertain is it?” A purity percentage that answers neither is a number floating free of both chains.

What a traceable number looks like is documented in the reference-material literature. When the National Research Council Canada assigned a purity value to a candidate certified reference material for the peptide angiotensin II, the paper opens by stating that the purity value assignment of metrologically traceable peptide reference standards requires specialized primary methods. They used three independent methods, corrected each for related peptide impurities, combined them statistically, and measured the trifluoroacetic acid counterion separately (considered an impurity in this case at nearly 25% by mass). The result was reported as 691 ± 9 milligrams of peptide per gram of material (k = 2) — a value, an uncertainty, and a coverage factor (PMID 30143839).

The Bureau International des Poids et Mesures did the equivalent for a synthetic human C-peptide material used in an international laboratory comparison: more than 65 impurities were identified, confirmed, and accurately quantified, with a combined mass fraction of 83.3 milligrams per gram and an expanded uncertainty of 3.0 milligrams per gram (k = 2), and the paper states that the calibration hierarchy concept used for the quantification of individual impurities is described in detail (PMID 29862433).

Compare that with the typical certificate in this category: a purity figure to one decimal place, no uncertainty, no coverage factor, no named reference, no calibration date. It may well be a competent measurement. It is not a traceable one, in the sense the word carries in metrology, and the certificate does not claim it is.

What was in the vial when someone checked

The direct evidence on label-versus-contents comes mostly from anti-doping and forensic laboratories, which analyze products seized at borders or purchased from illicit sellers. That sampling frame is important and is discussed in the limits section below. Within it, the findings are consistent.

Amount. Antidoping Switzerland and the Cologne doping-control laboratory analyzed 1,190 products seized at the Swiss border. For 146 of them (12%) the label indicated peptide hormones or growth factors. Across the whole set, less than 20% of the products contained the claimed substance in the respective amount (PMID 28156209). A group led from a Danish hospital laboratory bought melanotan II vials from three online shops and quantified them. The total amount of melanotan II in vials ranged between 4.32 and 8.84 mg, although each shop claimed that vials contained 10 mg melanotan II. Vials from two of the three shops also carried unknown impurities ranging from 4.1 to 5.9% (PMID 24771717). The label said one number; the vials held between 43% and 88% of it.

Identity — the right molecule with something extra. The Cologne group characterized a black-market growth hormone product and found the protein was 192 amino acids long instead of 191, carrying an additional alanine at the N-terminus. In the same study, three growth-hormone-releasing peptide analogues were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue (PMID 29864719). A Ghent doping-control laboratory examined two black-market preparations sold as mechano growth factor and found the black market products were both C-terminal amidated analogues of human MGF — a modified form, not the human sequence (PMID 22328223). None of these would be caught by a label. A mass check catches them only if someone compares the measured mass with the expected one closely enough to see the difference — and for the amidated MGF the authors report that difference as a single mass unit.

Identity — a laboratory by-product sold as a product. The same Cologne group identified, in a black-market vial, Long-R³-IGF-I carrying a six-histidine purification tag still attached at the C-terminus. His-tags are added during production so the protein can be pulled cleanly out of a mixture; the authors note that when the tag sits at the N-terminus it is removed afterward by specific enzymes. This one was at the C-terminus, still attached. The authors' reading was that the material may rather be a by-product from biochemical studies than something made for sale (PMID 20675162). A vial with a lot number on it can hold someone else's leftover.

Identity — not what the name says. In a four-year survey of 337 confiscated products in Germany, the Cologne laboratory reported that 12.8 % accounted for peptide hormones and growth factors and listed among its notable findings the thymic hormone thymosin β4, and a fusion protein of unknown biological activity (PMID 25168622). And the French horse-racing laboratory LCH, analyzing three products sold online under the names TB500, TB1000 and SGF1000, reported that the content of the TB500/TB1000 products is not systematically consistent with the products' own descriptions, and that SGF1000 is mainly composed of sheep extracellular matrix (ECM) and blood proteins (PMID 36482504).

The pattern across more than a decade of this literature is the same in every study: the label is a claim, and the claim was often wrong in amount, in identity, or in both. In none of these cases did the presence or absence of a lot number decide anything. What decided it was that someone tested the vial.

What does the evidence not show?

Five honest limits on everything above.

1. None of this is evidence about any particular vendor, ours included. The seized-product studies analyze shipments customs officers chose to stop, and the melanotan study bought from shops selected because they were selling illegally. That is the floor of the market, sampled on purpose. It says nothing about the average listing, and it says nothing about any supplier whose vials were not in those studies.

2. The regulation quoted is not a standard this category is measured against. Part 211 governs the manufacture of finished drug products. A research-reagent catalogue does not represent itself as operating under it, and this page does not suggest it should. The text is here because it is the origin of the vocabulary and the clearest statement of what the vocabulary means.

3. A lot number is a printed string, and printing is free. Nothing about a lot number is self-verifying. The same is true of a lab name, a date, and a signature block. The number's only evidentiary weight is what it lets a buyer request — and whether the request is answered with documents that match.

4. Absence of metrological traceability is not evidence of a wrong number. The traceable route is expensive: the angiotensin II assignment took three orthogonal primary methods and a statistical combination, and the C-peptide characterization found more than sixty-five impurities using high-resolution mass spectrometry and a described calibration hierarchy. A routine laboratory can run an area-percent method without any of that and still report a number that is approximately right. The point is narrower: a bare percentage carries no stated uncertainty, so a reader cannot tell how right.

5. Most of the product analyses are old. The German survey covers 2010–2013, the Swiss study was published in 2017, and the melanotan purchases were published in 2015. Only the TB500/TB1000 analysis is recent (published 2022–2023). Markets change, and a 2012 finding about a German customs seizure is not a finding about a 2026 storefront.

What to ask for, given all that

A lot number becomes evidence only when it is exercised. Five requests turn a printed string into a record:

The lot number on the vial, matched to the lot number on the certificate. If the certificate does not name a lot, it describes the product in general, not the material in hand. The COA verification page covers the rest of that check.
Which material the lot number points to. The synthesis batch? A fill-and-finish lot drawn from a larger bulk lot? A relabeled lot from a different supplier? Under the federal definition a lot may be a specific identified portion of a batch, so the answer is legitimately allowed to be “a portion” — but the buyer should know which portion the certificate tested.
The instrument output for that lot, identified as such. The laboratory-record rule asks for all graphs, charts, and spectra tied to the lot tested. A chromatogram with the lot number and date on it is the minimum. What that chromatogram can and cannot show is covered on the HPLC purity page.
Whether a reserve sample of that lot exists. This is the single most informative question on the list, because almost nobody asks it. A supplier who has retained material from the lot can have it re-tested; one who has not cannot, whatever the certificate says.
The uncertainty, or at least the method. A percentage with no stated uncertainty and no named method is a number nobody can check. “How was this measured, and against what?” is the metrologist's question, and it is a fair one to ask of anyone publishing a figure.

A supplier who can answer all five has a lot number that means what the regulation says it should. A supplier who can answer none of them has a label. In this category the useful question was never “is there a lot number.” It is “what can be determined from it.”

Sources

21 CFR 210.3 — Definitions (batch; lot; lot number, control number, or batch number). ecfr.gov (text as of 2026-08-01, fetched 2026-08-29)
21 CFR 211.130 — Packaging and labeling operations. ecfr.gov
21 CFR 211.165 — Testing and release for distribution. ecfr.gov
21 CFR 211.170 — Reserve samples. ecfr.gov
21 CFR 211.188 — Batch production and control records. ecfr.gov
21 CFR 211.194 — Laboratory records. ecfr.gov
Joint Committee for Guides in Metrology. International vocabulary of metrology — Basic and general concepts and associated terms (VIM), 3rd edition. JCGM 200:2012, definition 2.41. bipm.org (PDF)
Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018 Oct;410(26):6719–6731. doi:10.1007/s00216-018-1272-7 · PMID 30143839
Li M, Josephs RD, Daireaux A, Choteau T, Westwood S, Wielgosz RI, Li H. Identification and accurate quantification of structurally related peptide impurities in synthetic human C-peptide by liquid chromatography-high resolution mass spectrometry. Anal Bioanal Chem. 2018 Aug;410(20):5059–5070. doi:10.1007/s00216-018-1155-y · PMID 29862433
Weber C, Krug O, Kamber M, Thevis M. Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. Subst Use Misuse. 2017 May 12;52(6):742–753. doi:10.1080/10826084.2016.1263665 · PMID 28156209
Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164–172. doi:10.1002/dta.1655 · PMID 24771717
Krug O, Thomas A, Malerød-Fjeld H, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018 Aug;41:1–6. doi:10.1016/j.ghir.2018.05.001 · PMID 29864719
Esposito S, Deventer K, Van Eenoo P. Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. Rapid Commun Mass Spectrom. 2012 Mar 30;26(6):686–692. doi:10.1002/rcm.6144 · PMID 22328223
Kohler M, Thomas A, Walpurgis K, Terlouw K, Schänzer W, Thevis M. Detection of His-tagged Long-R³-IGF-I in a black market product. Growth Horm IGF Res. 2010 Oct;20(5):386–390. doi:10.1016/j.ghir.2010.07.001 · PMID 20675162
Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014 Nov;70(11):1303–1311. doi:10.1007/s00228-014-1743-5 · PMID 25168622
Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023 Apr;15(4):458–464. doi:10.1002/dta.3421 · PMID 36482504